Navigation Links
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Date:9/4/2012

NEW YORK, Sept. 4, 2012  /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by Intercept.  The number of shares to be offered and the price range for the offering have not yet been determined.

BofA Merrill Lynch is acting as sole book-running manager for the offering.  BMO Capital Markets is acting as lead manager and Needham & Company, LLC, Wedbush PacGrow Life Sciences and ThinkEquity LLC are acting as co-managers. 

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, and there shall not be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com, or BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square New York, NY 10036, Telephone: (800) 414-3627 E-mail: bmoprospectus@bmo.com.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. PBC is a chronic autoimmune liver disease that may progress to cirrhosis and liver failure, and it is currently the fifth leading indication for liver transplant in the United States. OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has outlicensed the product candidate to Dainippon Sumitomo Pharma (DSP).

 


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Closes $30 Million Series C Financing
2. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
3. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
4. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
6. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
7. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
8. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
9. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
10. Global RFID in Healthcare and Pharmaceuticals Industry
11. Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Following receiving CE Marking in ... s AMAR is a major milestone for the country where the ... ound care market in Israel ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ...
(Date:2/24/2017)... and Markets has announced the addition of the "Hemophilia Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Hemophilia ... market? What are the unit prices and annual treatment ...
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
Breaking Medicine Technology:
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
(Date:2/26/2017)... Philadelphia, PA (PRWEB) , ... February 26, 2017 , ... ... products and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for ... , Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
Breaking Medicine News(10 mins):